Fig. 2

Bone absorption markers were significantly inhibited in the early stages of denosumab administration, whereas bone formation markers were gradually inhibited by denosumab. a In the denosumab alone group, serum TRACP-5b was significantly inhibited from 1 week to 4 months. TRACP-5b reached its minimum value at 1 month. In the BP pre-treated group, TRACP-5b was also significantly inhibited from 1 week to 4 months, albeit less than in the denosumab alone group. Group comparisons showed significant differences before administration and at 1 week of administration. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences. b In the denosumab alone group, urinary NTX was significantly inhibited from 1 week to 4 months. Urinary NTX reached its minimum value at 2 months. In the BP pre-treated group, urinary NTX was also significantly inhibited from 1 week to 4 months, albeit less than in the denosumab alone group. Group comparisons showed a significant difference before administration. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences. c In the denosumab alone group, BAP peaked at 1 month, but then decreased to a significant value at 4 months. In the BP pre-treated group, BAP did not change significantly during the observation period. Group comparisons showed a significant difference at 1 month. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences. d In the denosumab alone group, P1NP was significantly decreased at 2 and 4 months. In the BP pre-treated group, P1NP did not change significantly during the observation period. Group comparisons showed significant differences from 1 week to 4 months. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences